Sign In
Buy FUSN
$13.26
+0 (+0%)
At Close: Sep 04, 2020
Trump administration backs nuclear fusion — as a company tied to Trump invests in it
10:00am, Monday, 18'th May 2026
Trump Media & Technology is set to merge with a fusion power company, as the broader fusion sector is seeing new regulations and receiving boosts from the White House.
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline
03:00pm, Thursday, 20'th Feb 2025
AstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate cancer.
Acquisition of Fusion Pharmaceuticals Completed
04:05pm, Tuesday, 04'th Jun 2024
HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), annou
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
04:05pm, Friday, 31'st May 2024
HAMILTON, ON and BOSTON, May 31, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as pre
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
04:05pm, Wednesday, 29'th May 2024
HAMILTON, ON and BOSTON , May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as prec
AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancer HAMILTON, ON and BOSTON , May 9, 2024 /PRNewswire/ -- Fusion Pharmaceuti
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Fusion Pharm
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
07:00am, Tuesday, 07'th May 2024
Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 02'nd May 2024
Fusion Pharmaceuticals (FUSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
10:26am, Friday, 26'th Apr 2024
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
04:34pm, Thursday, 25'th Apr 2024
HAMILTON, ON and BOSTON , April 25, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as pr
Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
07:20pm, Tuesday, 23'rd Apr 2024
Fusion Pharmaceuticals Inc. (FUSN) concluded the recent trading session at $21.42, signifying a +0.63% move from its prior day's close.
Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
06:56pm, Thursday, 11'th Apr 2024
In the most recent trading session, Fusion Pharmaceuticals Inc. (FUSN) closed at $21.36, indicating no shift from the previous trading day.
Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who received prior lutetium-bas
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN
07:48pm, Tuesday, 26'th Mar 2024
NEW YORK , March 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securi
